Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2530${count})

  • T2T Validation - NOD2, 2025
    Inflammatory and Regulatory Functions of NOD2 in the Setting of Parkinson’s Disease

    Study Rationale: NOD2 is a signaling protein which has been found to be more abundant and more active in brain tissues of patients with Parkinson’s disease. Certain changes in the sequence encoding...

  • Research Grant, 2024
    SUPPLEMENT: MJFF Consortium on PRKN and PINK1

    Study Rationale: Recessively inherited forms of Parkinson’s disease (PD) caused by mutations on both copies of the genes PRKN and PINK1 are unique in many aspects. Age at onset is mainly before the...

  • Research Grant, 2024
    Virtual Screening and Biochemical Confirmation of Small Molecule Activators of ATP10B

    Study Rationale: Disruption of lysosomal glucosylceramide (GluCer) homeostasis is a key risk factor in Parkinson’s disease. ATP10B, a lysosomal GluCer exporter, has been linked to Parkinson’s through...

  • Therapeutic Pipeline Program, 2024
    Integrin CLOAKs as Novel Oral Therapeutics for Parkinson’s Disease

    Study Rationale: Increased neuroinflammation promotes neuron injury and loss (neurodegeneration) and drives progression of Parkinson’s Disease (PD), suggesting that controlling neuroinflammation is an...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.